The Future of Healing Is Cellular
For decades, the standard answer to a syringomyelia or spinal cord injury diagnosis has sounded something like this: manage your symptoms, consider surgery when things get worse, and wait. Wait for research. Wait for trials. Wait for medicine to catch up to what your body is already telling you.
We built the I AM HEARD Coalition because we refused to accept that answer.
And right now — in labs, in clinical trials, and in real patients' bodies — the science is starting to catch up in a way that genuinely excites us. Cell therapy is no longer science fiction. It is one of the fastest-growing fields in all of medicine, and for the conditions our community lives with every day, the implications are profound.
Here is what the research is showing, and why we believe it matters for you.
What Is Cell Therapy?
Cell therapy is exactly what it sounds like: using living cells — or signals from those cells — to repair, regenerate, or protect damaged tissue. The most well-known form is stem cell therapy, which uses specialized cells capable of becoming other cell types to rebuild what has been lost or damaged.
Within the nervous system and spinal cord, researchers are focusing on several approaches:
Mesenchymal Stem Cells (MSCs) — derived from bone marrow, umbilical cord tissue, or fat; shown to reduce inflammation, protect neurons, and promote regeneration
Neural Stem Cells (NSCs) — cells that can differentiate into neurons, astrocytes, and other neural tissue
Induced Pluripotent Stem Cells (iPSCs) — patient's own cells reprogrammed into a stem-like state, reducing rejection risk
Exosomes — tiny vesicles released by stem cells that carry regenerative signals to damaged tissue without the risks of injecting living cells directly
Each of these represents a different tool in an emerging toolkit — and the data coming in is encouraging.
What the Research Is Showing
Spinal Cord Injury: Real Numbers, Real Patients
A landmark 2025 meta-analysis published in Spine reviewed human studies of mesenchymal and embryonic stem cell therapy for spinal cord injury and found:
43.3% of SCI patients receiving stem cell therapy experienced an improvement in their overall ASIA impairment scale grade
73.6% demonstrated improved sensory scores
49.4% showed improvements in motor function
Improvement was significantly higher than the 9.6% seen in placebo groups
Side effects were mild and transient — primarily headache and musculoskeletal discomfort that resolved without intervention
For context: a condition that was once considered largely untreatable is now showing meaningful improvement nearly half the time, with a safety profile that rivals over-the-counter medications.
A separate BMC Medicine meta-analysis of 58 clinical studies found that stem cells improved motor function in 48.9% of spinal cord injury patients — along with urinary function improvements in 42.1% and gastrointestinal function in 52%.
And Mayo Clinic's own research, published in 2024, concluded that stem cell regenerative therapy is safe for subacute and chronic spinal cord injury patients, with zero serious adverse events reported.
Syringomyelia: A Case That Stopped Us in Our Tracks
In a case study published in the World Journal of Stem Cells, a syringomyelia patient treated with uncultured umbilical cord-derived mesenchymal stem cells saw her syrinx cavity almost completely disappear two years after treatment — a result the researchers described as the condition being "deemed cured."
This was only the fourth documented case of stem cell therapy for syringomyelia in medical literature. Four cases is not a clinical trial. We are not saying this is a cure. But for a condition where "management" has been the ceiling for most patients, the possibility that a syrinx could reduce — and even resolve — is a signal worth following.
The researchers concluded that MSC transplantation "plays a positive role in the treatment of syringomyelia patients" and called explicitly for well-controlled, large-scale clinical studies. We agree. And we will be watching.
The Next Frontier: Exosomes
One of the most exciting developments in cell therapy is not about injecting stem cells at all. It is about exosomes — tiny nano-sized particles that stem cells release, carrying proteins, RNA, and signaling molecules that tell surrounding tissue to repair itself.
Why does this matter? Because exosomes offer many of the regenerative benefits of stem cells while eliminating several of their risks:
No risk of tumor formation from uncontrolled cell growth
No immune rejection
Can be manufactured at scale and stored
Cross the blood-brain barrier more effectively than whole cells
A 2025 review in Stem Cell Research & Therapy found that MSC-derived exosomes reduce neuroinflammation, protect neurons from apoptosis, promote new blood vessel formation, and restore the integrity of the blood-brain barrier. In CNS Neuroscience & Therapeutics, researchers described exosome-based therapy as "a safer, more effective, and more accessible alternative to stem cell-based interventions" for neurological disease.
Clinical trials for exosome therapy in neurological conditions are expanding. The field is still early. But the trajectory is unmistakable.
The Market Is Following the Science
When capital follows research at this scale, it signals a fundamental shift — not hype.
The global stem cell therapy market was valued at $16 billion in 2025 and is projected to reach $59.7 billion by 2035 — a compound annual growth rate of over 12%, according to Precedence Research. BCC Research projects the broader regenerative therapy market reaching $43.8 billion by 2030 at a 21.3% annual growth rate.
This is not a niche — it is one of the fastest-growing sectors in all of medicine. And the conditions driving that growth include exactly the spinal cord and neurological disorders that define our community.
In December 2024, the FDA approved Ryoncil — the first-ever MSC therapy to receive FDA approval — marking a milestone that signals regulatory confidence in the class of therapy as a whole. The door is open.
Why This Matters to Our Community Specifically
For patients with syringomyelia, Chiari malformation, spinal cord injuries, EDS, and related conditions, the implications of advancing cell therapy are not abstract.
These are conditions characterized by structural damage, chronic inflammation, nerve compression, and disrupted fluid dynamics — all mechanisms that cell therapy directly targets. MSCs do not just replace cells. They modulate immune responses, reduce the inflammatory environment that worsens symptoms, and send signals that promote healing in surrounding tissue. For a community where inflammation and nerve damage are daily realities, that is not a small thing.
We are also watching the intersection of cell therapy with less-invasive delivery methods— intrathecal (spinal fluid) injection rather than open surgery, intranasal exosome delivery, and systemic IV administration — all of which are being actively researched and bring these therapies closer to patients who cannot tolerate major surgical intervention.
What We Are Doing About It
At the I AM HEARD Coalition, we do not just observe the science. We track it, share it, and advocate for the patient community to have a seat at the table when research priorities are set.
Our research summaries focus specifically on less-invasive and emerging treatments — because we believe patients deserve to know what is on the horizon, not just what is already approved. We are building a community where research priorities are shaped by the people who live with these conditions, not only by the institutions that study them.
The science is moving. We intend to move with it — and to make sure our community is never the last to know.
This post is for educational purposes only and does not constitute medical advice. Always consult with your physician before making any treatment decisions.
Sources: World Journal of Stem Cells | Sage Journals 2025 Meta-Analysis | BMC Medicine | Mayo Clinic | Stem Cell Research & Therapy | CNS Neuroscience & Therapeutics | Precedence Research | BCC Research
